Last update 11 Dec 2024
Rituximab biosimilar(Center of Molecular Immunology)
Last update 11 Dec 2024
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms CIMAbior, RituxCIM, Rituximab biosimilar |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CU (01 Apr 2017), |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 27145L
The sequence is quoted from: *****
Sequence Code 83181H
The sequence is quoted from: *****
Related
2
Clinical Trials associated with Rituximab biosimilar(Center of Molecular Immunology)Safety and effectiveness of CIMAbior® in patients with CD20-positive B-cell Non-Hodgkin Lymphoma. Phase IV
Evaluation of the effect and safety of RituxCIM (biosimilar Rituximab) in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma
100 Clinical Results associated with Rituximab biosimilar(Center of Molecular Immunology)
Login to view more data
100 Translational Medicine associated with Rituximab biosimilar(Center of Molecular Immunology)
Login to view more data
100 Patents (Medical) associated with Rituximab biosimilar(Center of Molecular Immunology)
Login to view more data
100 Deals associated with Rituximab biosimilar(Center of Molecular Immunology)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Non-Hodgkin Lymphoma | CU | 01 Apr 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | Rheumatoid Arthritis CD19 | CD20 | IgG | 29 | htizaafhxk(uhbbjdesui) = yxfqsenjsl ixsqsjhvko (doaauoknyl ) View more | - | 02 Jun 2021 | ||
htizaafhxk(uhbbjdesui) = aqdhagiqia ixsqsjhvko (doaauoknyl ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free